FARMACIA HOSPITALARIA最新文献

{"title":"Hematopoietic stem cell transplantation as a team effort: Multidisciplinarity as the key to success.","authors":"Anna Sureda","doi":"10.1016/j.farma.2026.10.001","DOIUrl":"https://doi.org/10.1016/j.farma.2026.10.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crisantaspase desensitization with enzymatic activity monitoring in an adult patient with T-cell acute lymphoblastic leukemia and L-asparaginase hypersensitivity.","authors":"Diego Zamora-Sánchez, Adriana Pérez Rodríguez, Oreto Ruiz-Millo, Daniel López Otero, Miriam Panero Ruiz, Victoria López Calatayud, Mónica Climente Martí","doi":"10.1016/j.farma.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.006","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical experience with anti-interleukin-5 monoclonal antibodies in the treatment of eosinophilic granulomatosis with polyangiitis.","authors":"Elena Benito Arribas, Elena Villamañán Bueno, Daniel Laorden Escudero, Carlos Carpio Segura, Ana Noblejas Mozo, Leticia de Las Vecillas Sánchez, Gema Bonilla Hernán, María Aguilar Moreno, Rodolfo Álvarez-Sala Walther, Alicia Herrero Ambrosio","doi":"10.1016/j.farma.2026.08.010","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.010","url":null,"abstract":"<p><strong>Objective: </strong>Eosinophilic granulomatosis with polyangiitis is a rare disease whose standard treatment includes systemic glucocorticoids, bronchodilators, and immunosuppressive agents. Mepolizumab and benralizumab have recently emerged as therapeutic alternatives. The aim of this study was to evaluate the effectiveness and treatment outcomes in real-world practice.</p><p><strong>Methods: </strong>This retrospective observational study included 29 adult patients with eosinophilic granulomatosis with polyangiitis treated with mepolizumab and/or benralizumab at Hospital Universitario La Paz since 2017. Data were collected on oral glucocorticoid use, asthma therapies, immunosuppressive agents, eosinophil counts, and quality-of-life questionnaires to assess changes from baseline.</p><p><strong>Results: </strong>The mean initial dose of prednisone was 15.4 mg per day. At six months, 60.9% of evaluable patients had reduced their dose, and at one year, glucocorticoids had been completely discontinued in 11 of 23 evaluable patients. Five patients continued on immunosuppressive therapy, while the rest discontinued it. Eosinophil counts decreased significantly at one year. Quality-of-life measures showed numerical improvements after one year of treatment.</p><p><strong>Conclusion: </strong>In this real-world cohort, treatment with mepolizumab or benralizumab was associated with reduced glucocorticoid use and eosinophil counts. Some patients continued to require concomitant immunosuppressive therapy, particularly those with more complex disease presentations.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world adherence to biologic therapies targeting interleukin 17, interleukin 23 and ustekinumab in moderate-to-severe psoriasis: A multicenter cohort study.","authors":"María Calvo-Arbeloa, Ramón San Miguel-Elcano, Amaya Arrondo-Velasco, Maite Sarobe-Carricas, Joaquín Borrás-Blasco","doi":"10.1016/j.farma.2026.09.002","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.002","url":null,"abstract":"<p><strong>Objectives: </strong>Biologic therapies targeting interleukin IL-17, IL-23 and IL-12/23 have substantially improved outcomes in patients with moderate-to-severe psoriasis. In real-world settings, treatment effectiveness depends not only on drug efficacy but also on patient adherence, which is essential for the appropriate interpretation of treatment persistence. The objectives of the present study were to evaluate adherence to biologic therapy with IL-17 inhibitors, IL-23 inhibitors and IL-12/23 inhibitors in patients with moderate-to-severe psoriasis in real-world clinical practice and to identify factors associated with high adherence.</p><p><strong>Methods: </strong>A retrospective, multicenter observational study was conducted in one tertiary hospital and two regional hospitals within the same regional public healthcare system. Adult patients with moderate-to-severe psoriasis treated with IL-17 inhibitors, IL-23 inhibitors or IL-12/23 inhibitors for at least 4 months were included. Adherence was assessed using the medication possession ratio (MPR), calculated as the mean adherence across all dispensations recorded between December 2009 and October 2025. Multivariable logistic regression (with patient-level clustering to account for repeated courses) identified factors associated with excellent adherence (MPR ≥90%).</p><p><strong>Results: </strong>A total of 423 patients and 626 treatment courses were included. Mean overall adherence was 94.5%. Adherence ≥80% was observed in 97.4% of treatment courses, and 78.8% achieved adherence ≥90%. Older age, female sex and treatment with IL-23 inhibitors were independently associated with excellent adherence.</p><p><strong>Conclusions: </strong>Adherence to biologic therapies targeting interleukin IL-17, IL-23 and IL-12/23 in patients with moderate-to-severe psoriasis managed in hospital settings for at least 4 months is very high. Systematic assessment of adherence is essential for interpreting clinical outcomes and is essential for persistence analyses.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compliance of pediatric three-chamber parenteral nutrition bags with European guidelines: A complementary analysis.","authors":"Ivan Maray, Maite Pozas, Belén Rodríguez Marrodán, Mario Fuentes Herrero, Concepción Álvarez Del Vayo-Benito, Raquel Aguilar-Salmerón, Maite Bosch-Peligero, M José Cabañas Poy, Carmen Gallego Fernández, Yolanda Hernández Gago, Maria Goretti López-Ramos, Javier Corazón Villanueva, Raquel Escrig, Cecilia M Fernández-Llamazares","doi":"10.1016/j.farma.2026.09.005","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.005","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Depression, stress and medication adherence in patients with type 2 diabetes: A crosssectional study in Mexico.","authors":"Fátima Del Carmen Portillo-Robledo, Marco Antonio León-Mazón, Laura Ávila-Jiménez, Christian Díaz de León-Castañeda, Cairo David Toledano-Jaimes","doi":"10.1016/j.farma.2026.08.006","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.006","url":null,"abstract":"<p><strong>Objective: </strong>To describe the level of adherence to pharmacological treatment and explore, using a bivariate analysis, its unadjusted association with mental health variables (depression and stress) in patients with type 2.</p><p><strong>Method: </strong>A cross-sectional study was conducted with 326 patients with T2D and beneficiaries of a multidisciplinary center of a social security institution in Morelos, Mexico. Sociodemographic, clinical, and mental health variables such as stress and depression were evaluated, in addition to adherence to pharmacological treatment in patients with T2D, using instruments with evidence of validity and reliability. Bivariate statistical analysis was used to evaluate the association between the variables of interest and pharmacological adherence.</p><p><strong>Results: </strong>A statistically significant association was found between pharmacological adherence with depression (χ² = 7.3, p = 0.01; OR = 0.28, p = 0.01), and with depression and stress as concomitance (OR = 0.18, p = 0.02). No statistically significant associations were found with sociodemographic factors.</p><p><strong>Conclusions: </strong>In this cross-sectional study, a bivariate association was observed between depression-and its co-occurrence with stress-and pharmacological adherence. These findings should be interpreted with caution and require confirmation through studies with adjusted analyses.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] The \"Trojan horse\" against antimicrobial resistance: Siderophore conjugates and public health.","authors":"Alina Dammar Herrera-Callo, Marco Roberto Chávez-Morán","doi":"10.1016/j.farma.2026.04.018","DOIUrl":"https://doi.org/10.1016/j.farma.2026.04.018","url":null,"abstract":"<p><strong>Objective: </strong>Antimicrobial resistance, particularly in carbapenemase-producing Enterobacterales such as KPC-type, represents a critical threat to public health in Latin America, associated with high mortality rates and increased healthcare costs. This systematic review aims to evaluate the therapeutic potential of siderophore-drug and siderophore-peptide conjugates against priority multidrug-resistant pathogens, including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, analyzing their efficacy, mechanisms of action, and implementation challenges.</p><p><strong>Method: </strong>A systematic search was conducted in the PubMed, Scopus, and Web of Science databases up to August 2025. Key terms such as \"siderophore conjugates\", \"Trojan horse antibiotics\", \"antimicrobial resistance\", and \"Gram-negative bacteria\" were used. Preclinical and clinical studies, reviews, and meta-analyses published between 2019 and 2025 were included, selecting 55 references based on relevance to the topic, currency, and methodological quality. This review is a narrative review with a systematic literature search, developed in accordance with PRISMA guidelines.</p><p><strong>Results: </strong>Siderophore conjugates, via the \"Trojan horse\" mechanism, effectively exploit bacterial iron uptake systems to deliver antimicrobial agents in a targeted manner. They overcome key resistance mechanisms such as β-lactamase production, porin alterations, and efflux pump activity, while reducing systemic toxicity and preserving commensal microbiota. Clinical evidence (e.g., cefiderocol) and preclinical studies confirm their efficacy against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, achieving significant reductions in minimum inhibitory concentrations (MICs). However, critical challenges were identified: optimization of chemical stability and intracellular drug release, complexity in synthesis and industrial scaling under Good Manufacturing Practice (GMP) standards, and regulatory and logistical barriers in resource-limited settings.</p><p><strong>Conclusions: </strong>Siderophore conjugates offer a targeted therapeutic approach against multidrug-resistant pathogens by exploiting the bacteria's own iron-uptake systems. The available evidence ranges from clinical results with cefiderocol to preclinical developments with other platforms. Their application, however, faces challenges that span chemical optimization, manufacturing, regulation, and access in clinical settings.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dalbavancin and oritavancin in long-term suppressive therapy: Use, safety, dosing regimens and the role of therapeutic drug monitoring, protocol for a systematic review.","authors":"Raquel Gil-Bardaji, Carla Codina-Jiménez, Alba Martin Val, Maite Bosch-Peligero, Javier Diez de Los Rios, Esteban Reynaga Sosa, Marlene Álvarez Martins, Sergio Marin","doi":"10.1016/j.farma.2026.08.012","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.012","url":null,"abstract":"<p><strong>Objective: </strong>To develop a protocol for a systematic review aimed to evaluate the existing evidence on the use of dalbavancin and oritavancin as suppressive therapy, focusing on their efficacy, effectiveness and safety across different infectious diseases and therapeutic use protocols.</p><p><strong>Methods: </strong>A systematic review of studies involving patients treated with dalbavancin and/or oritavancin as suppressive therapy will be performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The main outcomes of interest are the efficacy, effectiveness and safety of these treatments as suppressive therapy. Searches will be performed in MEDLINE (PubMed), Embase (Ovid), the Cochrane Central Register of Controlled Trials, and the Latin American and Caribbean Health Sciences Literature database. English- and Spanish-language literature will be included, with no date restrictions. Studies including patients treated with dalbavancin and/or oritavancin as long-term suppressive therapy in adults will be included; studies in which these treatments were used for other purposes will be excluded. Reviews, abstracts, protocols, duplicates, and grey literature will be excluded. Data from the studies will be synthesised in both tabular and narrative form according to the Synthesis Without Meta-analysis reporting guidelines. Extracted data will include study design, patient characteristics, infection type, causative pathogens, dosing regimens, clinical outcomes, adverse events, and therapeutic drug monitoring targets and measurements. Data from these studies will be grouped by the drug(s) reported, infection type, isolated pathogen and used dosing regimens. The methodological quality of included studies will be assessed using the Joanna Briggs Institute critical appraisal tools. The article selection, data extraction, and quality assessment processes will be carried out by two independent reviewers, with a third to resolve discrepancies. This protocol has been reported to follow the recommendations stated by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. This protocol was registered in the International Prospective Register of Systematic Reviews of the Center for Reviews and Dissemination (registration number: CRD420251054127).</p><p><strong>Discussion: </strong>The current evidence on this topic is mainly limited to small studies, which show considerable variability in treatment schedules and reported outcomes. The protocol for this systematic review is the first step to synthesise evidence on this topic to support decision-making.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Codes of conduct in the relationship between hospital pharmacy services and industry.","authors":"Josep M Guiu-Segura, Montserrat Viñas-Bastart, Pilar Modamio","doi":"10.1016/j.farma.2026.09.003","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.003","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported experiences of heart failure patients regarding their pharmacotherapy following emergency department discharge: Red-IC-URG project.","authors":"Jesús Ruiz Ramos, María Muñoz García, Ana de Lorenzo Pinto, Daniel Gómez Costas, Ana Ginés Palomares, M Rosario Santolaya Perrin, Cristina Calzón Blanco, Ana López Pérez, Yolanda Castellanos Clemente, Cristina Puivecino Moreno, Mariam Hijazi Vega, Joan Ramon Roma Mora, Ana Fernández Ruiz Morón, Ester Bofill Roig, Beatriz Calderón Hernanz","doi":"10.1016/j.farma.2026.06.010","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.010","url":null,"abstract":"<p><strong>Objective: </strong>To assess pharmacotherapy-related experiences in patients with heart failure after emergency department discharge, as well as treatment knowledge, adherence, and understanding of treatment changes.</p><p><strong>Method: </strong>Multicentre prospective observational study conducted in 11 Spanish hospitals between April 2025 and February 2026. Adults with heart failure discharged home after decompensation were included. A structured telephone interview 3-7 days after discharge collected sociodemographic data, medication management variables, Morisky-Green adherence, experience with discharge information, and healthcare follow-up within 30 days.</p><p><strong>Results: </strong>Fifty-four patients were included; 57.4% were women and median age was 85 years (IQR: 75-87). Median number of discharge medications was 10 (IQR: 8-12), and perceived treatment complexity was 7/10 (IQR: 3-8). Overall, 38.9% did not know the purpose of their medications, 38.9% reported adverse effects, and 48.1% were adherent. Global experience with pharmacotherapy-related information was 9/10 (IQR: 8-10). Emergency department revisits at 30 days reached 31.5%.</p><p><strong>Conclusions: </strong>Although overall experience was positive, relevant barriers persisted in knowledge, autonomy, and adherence, supporting more structured transitional interventions with active involvement of hospital pharmacists.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149116280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}